CIK 0000715446
- Non-accelerated filer
- Smaller reporting company
Anixa Biosciences Inc
Sign in to watch- Ticker
- ANIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Oct 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 112622630
- Phone
- +1 408-708-9808
- Business address
- 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
- Former names
- ITUS Corp, COPYTELE INC
- 4 Open-market buy Director bought 30,000 shares at $4.21 ($126,300)
- 4 Open-market buy Chief Executive Officer bought 5,000 shares at $4.28 ($21,400)
- 4 Open-market buy Director bought 19,000 shares at $4.33 ($82,270)
- 4 Open-market buy Chief Executive Officer bought 10,000 shares at $3.94 ($39,400)
- 4 Open-market buy Director bought 12,200 shares at an average $3.99 ($48,730)
- 4 Open-market buy Director bought 20,065 shares at $3.96 ($79,457)
- 4 Open-market buy Director bought 20,000 shares at $3.90 ($78,000)
- 4 Open-market buy Director bought 23,300 shares at $3.72 ($86,676)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Other acquisition COO & CFO acquired 1,634 shares (other)
- 4 Open-market buy Director bought 10,000 shares at $4.49 ($44,900)
- 4 Open-market buy Director bought 10,000 shares at $3.91 ($39,100)
- 4 Open-market buy Director bought 5,000 shares at $3.99 ($19,950)
- 4 Open-market buy Director bought 45,000 shares at $4.84 ($217,800)
- 4 Open-market buy Director bought 15,600 shares at $4.88 ($76,128)
- 4 Open-market buy Director bought 10,000 shares at $4.80 ($48,000)
Page 6 of 24 · 471 filings